AB Sciex announces agreement to market MS solutions
AB Sciex and Indigo BioSystems have announced an agreement to jointly market mass spectrometry solutions that streamline data acquisition and automate data review to ensure high quality results in clinical research, forensic toxicology and pre-clinical and clinical trials of new drugs.
AB Sciex and Indigo BioSystems have announced an agreement to jointly market mass spectrometry solutions that streamline data acquisition and automate data review to ensure high quality results in clinical research, forensic toxicology and pre-clinical and clinical trials of new drugs.
This joint venture is expected to accelerate the use of new-generation mass spectrometry technologies for those who are accustomed to using easy-to-use lab analysers.
Joe Anacleto, vice president of Applied Markets and Clinical Research, AB Sciex, said, “Automation is an important step to accelerate the adoption of new-generation mass spectrometry for clinical research, forensics and clinical trials. Our relationship with Indigo BioSystems allows us to bring LC–MS–MS solutions to researchers who may not ordinarily consider mass spectrometry but can now have the assurance of a simplified workflow while getting all the attractive benefits of LC–MS–MS technology.”
Raul Zavaleta, Indigo CEO, commented, “By embedding the knowledge of assay experts into the analysis software, we provide the foundation for smarter research laboratories. We are pleased to be partnering with the industry leader in LC–MS–MS to achieve this goal.”
For more information please visit ref="http://www.absciex.com">www.absciex.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
